Tenax Therapeutics Unveils Phase 3 LEVEL Study Results at ESC Congress 2026
Tenax Therapeutics to reveal Phase‑3 LEVEL study results for TNX‑103 at ESC 2026, showing a 55‑meter 6MWD gain and solid safety in PH‑HFpEF.
3 minutes to read
TENAX THERAPEUTICS INC
Tenax Therapeutics Names Thomas Staab CFO to Strengthen PH‑HF‑pEF Pipeline
Tenax Therapeutics names Thomas Staab CFO to strengthen finances for levosimendan‑based PH‑HF‑pEF drug development, boosting investor confidence and capital strategy.
2 minutes to read
Tenax Therapeutics: Leveraging Levosimendan to Target PH‑HFpEF—Stock, Valuation & Future Outlook
Explore Tenax Therapeutics, a biotech firm targeting pulmonary hypertension and heart failure with levosimendan, its stock trends, and valuation insights.
3 minutes to read